Additionally, other potential confounders, such as factors affecting the physician's prescription preferences, were not accounted for and we cannot rule out confounding by indication
Therefore, it is not advisable to use Semaglutide GLP-1 for weight loss unless you meet the approved criteria and are under the care of a licensed healthcare professional who can evaluate your health history, monitor your progress, and determine if the treatment is safe and appropriate for your needs
Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer
Instead, it offers brand-name Ozempic and Wegovy from Novo Nordisk and Zepbound from Eli Lilly
What we see in the mirror may not reflect how people feel on the inside
On 1 April 2026, the FDA approved Foundayo (orforglipron) for adults with obesity or overweight with weight-related medical conditions, making it the first small-molecule oral GLP-1 receptor agonist to receive regulatory clearance anywhere in the world